BNGOBionano Genomics, Inc.
1.200USD-2.44%Mkt Cap: 14.13M $P/E: —3d ago
Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers …
Industry Peers
Medical Instruments & Supplies$135.72BUSDP/E 43.4
$81.53BUSDP/E 30.5
$52.30BUSDP/E 33.2
$46.09BUSDP/E 42.8
$35.59BUSDP/E 56.2
$32.44BUSDP/E 55.0
$33.40BUSDP/E 22.2
$24.85BUSDP/E 45.2
$20.46BUSDP/E 64.5
$18.52BUSDP/E 86.9
$16.89BUSDP/E 40.2
$14.73BUSDP/E 69.1
$15.25BUSDP/E 10.9
$14.87BUSDP/E 64.6
$13.62BUSD
$11.55BUSDP/E 27.6
$10.22BUSDP/E 244.8
$9.78BUSD
$8.57BUSDP/E 24.3
$6.08BUSDP/E 24.8
| Headline | Source | Time |
|---|---|---|
Older | ||
 Bionano Genomics (BNGO) Q2 2026 Earnings Call Transcript Flow cell sales surged 27% as OGM adoption accelerates globally. | ||
Bionano Genomics Inc (BNGO) (Q2 2026) Earnings Call Highlights: Record Flow Cell Sales and ... Bionano Genomics Inc (BNGO) reports 21% revenue growth in Q2 2026, driven by record flow cell sales and improved gross margins, while navigating supply constraints and liquidity concerns. | ||
 Bionano Genomics, Inc. Q2 2026 Earnings Call Summary Moby summary of Bionano Genomics, Inc.'s Q2 2026 earnings call | ||